Get started

Stocksignals

C3.AI is a great buy opportunity for the rest of the year.C3.ai (AI) has been trading within a Channel Down pattern for more than 1 year (since the August 01 2023 High) and yesterday it almost hit its bottom (Lower Lows trend-line). The 1D RSI breached below the 30.00 oversold barrier, and within this 1 year, it has always been a buy signal. However we can't rule out an extended consolidation or even a slightly Lower Low within those levels until the price recovers fully, but on the long-term and particularly until the end of the year, C3.ai presents a strong buy opportunity on the current level. The previous two Bullish Legs topped on the 0.785 Fibonacci retracement level, so our Target is 28.50 (marginally below it). ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:AILong
by TradingShot
Double-Top In PlayAs expected, SPY double-top looks to be playing out. I don't expect us to drop much lower than the pink ascending trendline. Maybe we'll touch that 200 dma before our full send. Let me remind you that the pink ascending tl is the neckline of a large cup and handle pattern on the bi-weekly, the target of which remains 650-700. This is still in play on the longer timeframe and as long as we don't break below the pink tl with confirmation on the weekly, I will start to buy back at or around the pink tl and down to the 200 dma. Batting 1000% thus far and hoping to keep it perfect.
AMEX:SPYShort
by stewdamus
1
TESLA broke above the 2-month Resistance and is aiming for $300Last month (August 15, see chart below) we gave a pull-back buy signal on Tesla (TSLA) and the price action swiftly responded with a August 28 Low and then rebound: The rebound was on the 1D MA200 (orange trend-line) and today we see a strong bullish break-out above the 1D MA50 (blue trend-line). This alone is enough to confirm the start of the next phase of the Bullish Leg, since the long-term pattern is a Channel Up, as closing above 228.00 will constitute a Higher High. Technically the structure is similar to the previous mid-Bullish Leg consolidation (April 30 - June 24), even the 1D MACD sequences between the two fractals are similar. In that sense we can't rule out some more ranged trading for September but on the long-term our Target remains unchanged. We expect the $300 level to break before November. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NASDAQ:TSLALong
by TradingShot
ROCKET LAB has started a new 9-month correction phase.Rocket Lab USA (RKLB) topped on August 19 after a more than +100% rise from the bottom that eventually reached the top of the Sine Wave count and as a result even though it failed to reach our $8.75 mark (Target 2), we will take profit on the last buy signal we issued (May 29, see chart below): As you can see by the Sine Waves, RKLB is repeating a 2-year cyclical pattern (since the June 30 2022 bottom), which every time it provides a buy opportunity that delivers a little over +100% return (3 times so far within this time span). Now that we got our +111% rise, we expect a new multi-month correction phase to start, initially in the form of a Channel Down (red). The previous correction phase lasted for 9 months and the one before for 10 months, before the +100% rallies commenced. As a result, we are far away from a buy opportunity at the moment and the best course of action is to short below even the 1D MA200 (orange trend-line). Our Target is $4.35, the middle of the High Volatility Zone, which is located just above the (green) Support Zone, where our next long-term buy will be. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NASDAQ:RKLBShort
by TradingShot
1
NETFLIX starting the 2nd bullish leg of its expansion phase.Netflix (NFLX) has been consolidating above the 1D MA50 (blue trend-line) since the August 20 High and is on the exact same level where during all previous Bullish Legs of the 2-year Channel Up, it ended the consolidation and moved to the 2nd rally of the expansion phase. This is also evident on the 1D RSI, which is about to start a Channel Down that in previous Legs it moved parallel with the price's 2nd rally. Our Target is $900.00 representing a +70.48% rise from April's low, which is the smallest rally recorded within the 2-year Channel Up, thus the more realistic target. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NASDAQ:NFLXLong
by TradingShot
S&P500 The Bull Cycle is still far from over!Six months ago while the market was undecided about whether or not the S&P500 (SPX) rally would continue, we presented a very useful multi-year chart on the 1M time-frame (February 27, see chart below), where we called for an extension of the uptrend, claiming confidently that the 'Bull Cycle is far from over': As you can see those who bought without fear have enjoyed so far more than +15% gains. What's even more impressive is the massive bullish reversal of the August candle, that managed to close the month in green, despite the early aggressive sell-off. This is a strong sign that the rally is far from over, but it's not the only one. The key here, and constitutes our main modification relative to the chart 6 months ago, is that the most accurate sell signal on a cyclical basis has been historically given after the 1M RSI breaks above the 70.00 overbought barrier and posts Lower Highs. This signal has had 100% accuracy in the past 10 years, effectively projecting the 2015, 2018 and 2022 corrections. The 1M RSI also has a Channel Down Resistance to consider but the Lower Highs signal should be top priority for investors to start selling. As a result, we expect the index to surpass the 6000 mark and even approach 6500, before we consider a cyclical selling sequence again. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
TVC:SPXLong
by TradingShot
5
Axis bank has a chance to ace it..Axis Bank Ltd. engages in banking and financial services. It provides financial solutions to retail, small and medium enterprises, government, and corporate businesses. It operates through the following segments: Treasury, Retail Banking, Corporate or Wholesale Banking, and Other Banking Business. The Other Banking Business segment encompasses para banking activities such as third party product distribution advisory and other banking transactions. Axis Bank Ltd. CMP is 1188.80. The positive aspects of the company are low Valuation (P.E. =13.8), Company with Zero Promoter Pledge, Increasing Revenue every Quarter for the past 8 Quarters, Mutual Funds Increased Shareholding over the Past Two Months, MFs increased their shareholding last quarter and Book Value per share Improving for last 2 years. The Negative aspects of the company are Poor cash generated from core business, declining Cash Flow from Operations and Increase in Provisions in the recent results. Entry can be taken after closing above 1191 Targets in the stock will be 1206, 1243 and 1270. The long-term target in the stock will be 1292, 1313 and 1337. Stop loss in the stock should be maintained at Closing below 1127. The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
NSE:AXISBANKLong
by Happy_Candles_Investment
Canara Bank Can start after consolidation.Canara Bank engages in the provision of commercial banking and financial services. It operates through the following segments: Treasury, Corporate or Wholesale Banking, Retail Banking, and Other Banking Business. Canara Bank CMP is 112.77 The positive aspects of the company are low Valuation (P.E. =6.5), Annual Profit Growth higher than Sector Profit Growth, Increasing profits every quarter for the past 2 quarters, Company with Zero Promoter Pledge, Mutual Funds Increased Shareholding over the Past Two Months and FII / FPI or Institutions increasing their shareholding. The share has good dividend yield of 2.9% at CMP. The Negative aspects of the company is that the stocks is underperforming their Industry Price. Entry can be taken after closing above 114 Targets in the stock will be 117 and 122. The long-term target in the stock will be 124 and 129. Stop loss in the stock should be maintained at Closing below 105. The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
NSE:CANBKLong
by Happy_Candles_Investment
RIVIAN giving highly accurate signals within this Channel Down.Rivian Automotive (RIVN) couldn't have been giving us more accurate signals since May (see charts below), as not only did we get a timely entry at the bottom (chart 1, May 17) but also sold at the very top (June 26 chart 2) of the Channel Down: Right now we face a technical similarity with September 2023, exactly 1 year ago, where the price failed to utilize the 1D MA50 (blue trend-line) as Support and started a new long-term Bearish sequence. However we do realize the potential long-term trend changing effect that a potential new cycle of interest rate cuts might have in two weeks, so again our trading plan will prepare for both scenarios with clear break-out signals and levels. Obviously as long as the price remains within the 2-year Channel Down, the trend is bearish and the action will be 'sell on every high'. The Sell Signal on the September 2023 fractal was given when the 1D RSI hit the 60.00 level (red arrow, Sep 14 2023). Naturally we will wait for another such trigger to sell and Target 10.55 on the 0.5 Fibonacci retracement level, which is where last year's sell signal bottomed (October 30 2023). If on the other hand, the price closes a 1W candle above the 1W MA100 (yellow trend-line), we will buy that clear long-term bullish break-out signal and Target 28.00 (just below Resistance 2). This could emerge as a Channel Up pattern. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NASDAQ:RIVN
by TradingShot
Powergrid can become PowerfulPower Grid Corp. of India Ltd. is a holding company, which engages in the power transmission business. It operates through the following segments: Transmission Services, Consultancy Services, and Telecom Services. It is a PSU company with high dividend yield of 3.3% at current market price. Power Grid Corp. of India Ltd. CMP is 337.40 The positive aspects of the company are moderate Valuation (P.E. =20), Company with Zero Promoter Pledge, MFs increased their shareholding last quarter, Growth in Quarterly Net Profit with increasing Profit Margin and The Negative aspects of the company are Inefficient use of shareholder funds - ROE declining in the last 2 years and Declining Net Cash Flow : Companies not able to generate net cash. Entry can be taken after closing above 343. Targets in the stock will be 348 and 356. The long-term target in the stock will be 364. Stop loss in the stock should be maintained at Closing below 328 or 291 depending on your risk taking ability. The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
NSE:POWERGRIDLong
by Happy_Candles_Investment
Ultratech may make not ultra but mild upward moves. UltraTech Cement Ltd. is a holding company, which engages in the manufacture and sale of cement and cement related products. Its products include ordinary portland cement, portland blast furnace slag cement, white cement, and ready mix concrete. UltraTech Cement Ltd. CMP is 11301.90. The positive aspects of the company are Company with Low Debt, Company with Zero Promoter Pledge, Book Value per share Improving for last 2 years. The Negative aspects of the company are high Valuation (P.E. =46.5), PE higher than Industry PE, MFs decreased their shareholding last quarter, Declining Net Cash Flow : Companies not able to generate net cash. Entry can be taken after closing above 11380. Targets in the stock will be 11524 and 11707. The long-term target in the stock will be 11893 and 12096. Stop loss in the stock should be maintained at Closing below 10922. The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
NSE:ULTRACEMCOLong
by Happy_Candles_Investment
SMCI This is honestly the last stand.Super Micro Computer Inc. (SMCI) suffered yet another brutal sell-off following the announcement of a delay in filing its 10-K annual report. This may prove to be a catastrophic one as technically not only did it fail exactly on its 1W MA50 (blue trend-line) but also saw the stock test the bottom of its multi-year parabolic support, the Higher Lows Zone since the week of July 05 2022. This was basically the last time the 1W MA100 (green trend-line) got tested with the current week coming the closest since then. The 1W MA100 last broke during the unexpected COVID flash crash in March 2020, so technically it is the stock's longest Support. If it fails to hold and SMCI closes a 1W candle below it, the long-term parabolic growth pattern is invalidated and we will risk testing the 1W MA200 (orange trend-line) at a price potentially around $250.00. If on the other hand the 1W MA100 holds (and we will need the news sentiment to drastically reverse in order to achieve that, something that currently can't be seen on the horizon), then we can see another +400% long-term rally, in which case we estimate a Target around $2000, the stock's next critical psychological growth level. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NASDAQ:SMCI
by TradingShot
2
PALANTIR Correction starting. Short or wait to buy on that levelPalantir Technologies (PLTR) have been trading within a Channel Up since the May 04 2023 Low. Last week the price reached the pattern's top (Higher Highs trend-line) and technically we expect that to be the end of the recent Bullish Leg, as also indicated by the Sine Waves. Naturally we anticipate a medium-term pull-back in the form of a Bearish Leg. The previous 3 Bearish Legs have been under the form of Lower Highs that broke below the 1D MA50 (blue trend-line) and hit at least the 1D MA100 (green trend-line) before rebounding again into a new Bullish Leg. As a result, we expect to see at least a test of the 1D MA100, which short sellers can target $26.00. This is also above the minimum %correction we've seen inside this pattern (-25.90%). The strongest buy signal inside this long-term Channel Up is historically give when the 1D RSI hits the 35.85 - 30.20 Support Zone. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
PShort
by TradingShot
VISA Best buy opportunity since 2022.Visa Inc (V) is trading again above its 1W MA50 (blue trend-line) for the 3rd straight week following the rebound on early August's Low. That low apart from a Double Bottom is also a technical Higher Low formed at the bottom of the 2-year Channel Up. The previous Double Bottom in October 2023 was exactly on the 1W MA50 and even though not at the bottom of the Channel Up, it did manage to kickstart a +27.36% rally. The Bullish Leg before it rose by +34.04% before also correcting back to the 1W MA50. With the 1W MACD about to form the first Bullish Cross in 9 months, we have at hand the best buy opportunity on Visa, whose last 1W MACD this low was back on the September 2022 bottom! Our Target for the end of the year is $320.00 (+27.36%). ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:VLong
by TradingShot
SMCI Short-term buy opportunity within its corrective Channel. Super Micro Computer Inc. (SMCI) has been trading within a Channel Down pattern since the March 08 2024 High. Even though the trend on a multi-year basis is bullish, short-term investors should have this pattern in mind. Even on the shorter term though, the stock has managed to price a new Lower Low (August 08) at the bottom of the Channel Down and started its new Bullish Leg. Today's low opening has served as the first technical Higher Low on the Bullish Leg, potentially similar to the May 01 2024 Higher Low of that Channel Up. The 1D MACD has already completed a Bullish Cross, as on May 06 and naturally the next Target is a Higher High above the 1D MA50 (blue trend-line) again. We are aiming for $750.00 short-term. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NASDAQ:SMCILong
by TradingShot
8
How To Pick Top Pharma Stocks like a ProAnalyzing the pharmaceutical industry, whose products play a key role in improving the quality of life of people around the world, is quite challenging sometimes also it requires deep knowledge and a careful approach, as I believe that investors should consider many factors, starting with evaluating the efficacy of the analyzed company's medications, including in relation to its competitors and the "gold standards," and ending with an analysis of its financial indicators In this article you will learn how to pick Top Pharma stocks like a pro trader and which factors you should consider, so buckle up 1/ Recognizing the risks At the very beginning, an investor you must recognize that the pharmaceutical industry is highly competitive, where a company's investment attractiveness depends not only on the rate of expansion of its portfolio of product candidates, revenue growth, margins, the amount of total debt and cash on the balance sheet but is also heavily influenced by the expiration of patents on medications and vaccines. Moreover, in recent months, the healthcare sector has increasingly felt the impact of the upcoming 2024 US presidential elections, as some politicians are aiming to further tighten regulation of drug prices despite the existing Inflation Reduction Act. 2/ Leveraging data to your advantage The second step use data wisely, you should check all kinda data including stock screener, transcripts of earnings calls, financial results for the last quarters, analyst expectations, options data... The goal is to filter companies in poor financial condition, as well as those that trade at a significant premium to the sector and/or competitors I would also like to point out that in the current market environment, with Fed interest rates remaining at multi year highs, I do not recommend investing in companies with market caps below $500 million, as they typically have limited cash reserves and weaker institutional backing Also, I'd recommend investors read 10-Ks and 10-Qs, especially the section related to debt and sources of financing of the company's operations, to reduce the likelihood of an "unexpected" drop in the share price. A striking example is Invitae Corporation aka NVTAQ which declared bankruptcy in mid February 2024! Was there a prerequisite for this? The answer is yes since the company continued to generate negative cash flow and also had convertible senior notes maturing in 2028. Convertible notes can involve significant financial risks if the company cannot effectively use the cash to grow the business and break even. In this case, management will not be able to pay off the bonds with cash reserves and will have to resort to significant dilution of investors. In my opinion, Pacific Biosciences of California, Inc. NASDAQ:PACB may face this problem because it has convertible senior notes maturing in 2028 and 2030. Factors that concern me include the company's declining revenue and total cash and short-term investments in recent quarters, while its operating expenses remain extremely high at around $80 million per quarter. Let's return to the second step in my approach to selecting the most promising assets in the healthcare sector. When selecting companies with market caps between $4 billion and $40 billion, I use more parameters since most of them already have FDA approved drugs and/or vaccines. As a result, it is also necessary to consider the rate of growth of operating income, net debt/EBITDA ratio, and how management copes with increased marketing and production costs. Finally, let's move on to the last basket, which contains pharmaceutical companies with market capitalizations exceeding $40 billion. I think, this group is best suited for more conservative investors looking for assets offering attractive dividend yields and growing net income, supported by a rich portfolio of FDA approved and experimental drugs. So, from Big Pharma, I like Pfizer Inc NYSE:PFE , AbbVie Inc NYSE:ABBV , Merck & Co NYSE:MRK and AstraZeneca PLC NASDAQ:AZN . I also want to include Novartis AG NYSE:NVS and Roche Holding AG OTC:RHHBY in this group sometimes investors need to make exceptions, namely if one larger company buys out a smaller player and/or when a major partnership agreement is concluded, as was the case between Merck and Daiichi Sankyo Company, Limited OTC:DSKYF in 2023. Also, in the event of a major acquisition or merger, the company's debt may temporarily increase sharply. If its management has previously implemented effective R&D and financial policies, the "net debt/EBITDA ratio" A remarkable example of a company falling into the "value trap" is Takeda Pharmaceutical Company Limited NYSE:TAK , which overpaid for Shire. This deal did not significantly strengthen or rejuvenate the Japanese company's portfolio of drugs. As a result, it had to sell off billions of dollars in assets to pay off its debt partially. However, despite all the efforts of Takeda's management, its net debt/EBITDA ratio, although it fell below 5x, remains high, namely about 4.7x at the end of March 2024. 3/ Identifying promising therapeutic areas In general, the more prevalent a disease is, the larger the total addressable market for a drug and, as a result, the higher the chances that it will become a commercially successful product. Global spending on cancer medications will reach $377 billion by 2027, followed by immunology, and diabetes will come in third with an estimated spending of about $169 billion What challenges arise when choosing pharmaceutical companies? you should also keep in mind that the larger the market, the higher the competition between medicines, as companies strive to grab as big a piece of the pie as possible. As a result, for drug sales to take off, they need to have significant competitive advantages over the "gold standard." These competitive advantages may include greater efficacy in treating a particular disease, less frequent administration, a more favorable safety profile, and a more convenient route of administration. So, in recent years, competition in the global spinal muscular atrophy treatment market has intensified. Spinal muscular atrophy is a genetic condition. Currently, three drugs have been approved to combat the disorder, including Biogen Inc.'s (BIIB) Spinraza, Roche/PTC Therapeutics, Inc.'s (PTCT) Evrysdi, and Novartis AG's (NVS) gene therapy Zolgensma. All three products have similar efficacy, but Evrysdi has a more favorable safety profile and is the more convenient route of administration, namely the oral route, which is reflected in its sales growth rate from year to year. The second pitfall is the company's pipeline of experimental drugs. I believe that financial market participants opening an investor presentation that presents a company's pipeline, especially if its market cap is below $5 billion, should also pay close attention to what stage of clinical trial activity its experimental drugs are in. if a pharmaceutical company has most of its product candidates in the early stages of development, this represents a significant risk because, in this case, institutional and retail investors are often overly optimistic about the prospects for the drugs' mechanisms of action and/or clinical data obtained in a small group of patients. Simultaneously, as is often the case, the higher the optimism, the less favorable the risk/reward profile. In most cases, the larger and more diverse the patient population, the weaker the efficacy of a drug relative to what was seen in Phase 1/2 clinical trials. This ultimately leads to a downward valuation of its likelihood of approval and casts doubt on its ability to take significant market share from approved medications. This may subsequently reduce the company's investment attractiveness, making it more difficult to attract financing for its operating activities. As a result, I recommend excluding any company that, instead of focusing its financial resources on the most promising product candidates, conducts multiple early-stage clinical trials to evaluate the efficacy of its experimental drugs. In my experience, the most successful pharmaceutical companies focus their efforts on bringing up to three product candidates to market and then reinvesting the revenue from their commercialization into developing the rest of the pipeline. The table below highlights the following parameters that I use to screen out the least promising companies. A third factor that investors, especially those new to the investment world, should consider is that large pharmaceutical companies are leaders in certain therapeutic areas, with a rich portfolio of patents covering various mechanisms of action and delivery methods of drugs, making it more difficult and more prolonged for smaller players to find product candidates that could potentially have the competitive advantages. So, Novo Nordisk A/S NYSE:NVO and Eli Lilly and Company NYSE:LLY have long been leaders in the global diabetes and weight loss drugs markets, and only very recently, they may be joined by Amgen Inc. NASDAQ:AMGN , Roche Holding, and several other companies 4/ Assessing a company's drug portfolio in comparison to competitors Evaluating the effectiveness, safety profile, and mechanism of action of a medication, as well as comparing clinical data with its competitors, takes a lot of time and effort. I provided examples of drugs and the most promising mechanisms of action in the obesity treatment market. Their manufacturers are Eli Lilly, Novo Nordisk, Roche Holding, Viking Therapeutics, Inc, Amgen, Pfizer, Altimmune, Inc, OPKO Health, Inc, Boehringer Ingelheim, and Zealand Pharma A/S 5/ When market exclusivity for a company's key medications ends Every financial market participant who is considering investing in pharmaceutical companies should consider the expiration time of key patents of medicines. Marketing exclusivity represents protection against the entry of a generic version and/or biosimilar of a branded drug into the market, thereby allowing the company to recoup the resources spent on its development and, in the event of its commercial success, also reinvest the money received to accelerate the development of the remaining product candidates. Where can you find information about patent expiration dates? All the necessary information is either in 20-Fs/10-Ks or on the FDA website, namely in the "Orange Book" section. let's take Eli Lilly as an example. Open the latest 10-K. Then, the CTRL + F combination opens the ability to find specific words in the document. I usually enter "Expiry Date" or "compound patent" to find the patent section.nvestors can also find information about patents on the FDA website. As an example, I enter "Mounjaro" in the top line, and a list of patents opens that protect Eli Lilly's blockbuster from the introduction of its generic versions onto the market.hen, clicking on "Appl. No." will open information about the submission date of the patent and when it will expire. 6/ Evaluating the impact of insider share transactions The next step in selecting the most interesting assets in the healthcare sector is to analyze Form-4s. The CEO, CFO, and other key members of the company's management buy or sell shares from time to time.I am only interested in analyzing purchases since, most often, sales by management are option exercises carried out to pay taxes. When management starts making large outright purchases of a company's shares, it can signal that it believes in its long-term growth potential.if more than two top managers buy a large block of shares within two weeks of each other, it significantly increases the likelihood of the company's stock price rising in the next two months from the moment of their transactions But as with everything, there are exceptions, such as in the case of OPKO Health, which is developing a long-acting oxyntomodulin analog for the treatment of obesity together with LeaderMed Group.Over the past 12 months, OPKO's management, especially CEO Phillip Frost, has purchased over 12 million shares. However, despite this, its stock price has fallen by 27% over the same period. I believe that the key reasons for the divergence between these two facts are investors' lack of confidence in Phillip Frost's ability to make the company profitable again, as well as its low cash reserves. Therefore, companies like OPKO Health have already been eliminated at the second step of selection using Seeking Alpha's screener. 7/ CEO Performance in Business Development The CEO plays a crucial role in the success of a pharmaceutical company since the pharmaceutical industry is highly dynamic, and the competition between Big Pharma is especially high, I advise readers to pay attention to the track record of the CEO, especially how he copes with force majeure situations, as well as how effective the R&D policy is carried out under his leadership. 8/ Identifying Entry and Exit Points for Long-Term Investments The eighth step is in addition to the information that was obtained in the previous steps, as well as the analysis of financial risks and various financial metrics of the company, including its net debt, maturity dates of bonds, historical revenue growth rates, EBIT, gross margin, I build a DCF model with the ultimate goal of determining the price target. it is necessary to conduct a technical analysis of them, as well as the main ETFs that include them. In my opinion, the key ETFs are the SPDR® S&P Biotech ETF AMEX:XBI , Fidelity Blue Chip Growth ETF AMEX:FBCG , iShares Biotechnology ETF NASDAQ:IBB , and VanEck Pharmaceutical ETF $PPH. The purpose of technical analysis is to determine the stop-loss level and entry points at which the risk/reward profile is most favorable. taking profit is not that easy cuz you must master your emotions and greed which damn hard 9/ Creating a Watchlist Based on Risk/Reward Ratio The purpose of which is to create a watchlist of the companies I have selected based on the previous steps. I make several lists of companies based on their market caps and also rank them according to risk/reward profile, that is, in the first place is the stock that I think has minimal risks and at the same time can bring the greatest potential profit. I also advise creating small notes on each company, which can include information about risks, support/resistance zones, dates of publication of clinical data, and any thoughts you have that will make your decision more conscious when opening a position “What’s your secret sauce for choosing pharma stocks?”
NYSE:NVOEducation
by moonypto